$2975 | SAVE $525 | Single User
$5950 | SAVE $1,050 | Site License
$8925 | SAVE $1,575 | Enterprise License

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H2 2016
[Published by Global Markets Direct]

Published by Global Markets Direct: 26 Oct 2016 | 20634 | In Stock

Introduction

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H2 2016’, provides in depth analysis on C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted pipeline therapeutics.

The report provides comprehensive information on the C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)

- The report reviews C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics and enlists all their major and minor projects

- The report assesses C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H2 2016 [Published by Global Markets Direct]

  • Table of Contents

    Table of Contents 2

    List of Tables 4

    List of Figures 4

    Introduction 5

    Global Markets Direct Report Coverage 5

    C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Overview 6

    Therapeutics Development 7

    C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Products under Development by Stage of Development 7

    C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Products under Development by Therapy Area 8

    C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Products under Development by Indication 9

    C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Products Glance 10

    Late Stage Products 10

    Early Stage Products 11

    C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Products under Development by Companies 12

    C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Products under Development by Universities/Institutes 14

    C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Assessment 16

    Assessment by Monotherapy/Combination Products 16

    Assessment by Mechanism of Action 17

    Assessment by Route of Administration 19

    Assessment by Molecule Type 20

    C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Companies Involved in Therapeutics Development 22

    AFFiRiS AG 22

    ChemoCentryx, Inc. 23

    Dompe Farmaceutici S.p.A. 24

    Prommune, Inc. 25

    C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Drug Profiles 26

    avacopan - Drug Profile 26

    Product Description 26

    Mechanism Of Action 26

    R&D Progress 26

    DF-2593A - Drug Profile 31

    Product Description 31

    Mechanism Of Action 31

    R&D Progress 31

    Drug to Antagonize C5aR for Periodontitis - Drug Profile 32

    Product Description 32

    Mechanism Of Action 32

    R&D Progress 32

    EP-67 - Drug Profile 33

    Product Description 33

    Mechanism Of Action 33

    R&D Progress 33

    Small Molecule to Target C5aR for Undisclosed Indication - Drug Profile 34

    Product Description 34

    Mechanism Of Action 34

    R&D Progress 34

    Synthetic Peptide to Antagonize C5aR for Amyotrophic Lateral Sclerosis - Drug Profile 35

    Product Description 35

    Mechanism Of Action 35

    R&D Progress 35

    Vaccine to Target C5a for Alzheimer's Disease - Drug Profile 36

    Product Description 36

    Mechanism Of Action 36

    R&D Progress 36

    C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Dormant Projects 37

    C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Discontinued Products 39

    C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Featured News & Press Releases 40

    Jul 13, 2016: UNMC Researcher Secures .25 Million Grant to Fight Antibiotic Resistance 40

    Jun 16, 2016: ChemoCentryx Announces Positive Top-Line Results for CCX168 from the Phase II ANCA-Associated Vasculitis CLASSIC Study and Advances Plans to Initiate Phase III Development 40

    Jun 01, 2016: ChemoCentryx Receives European Medicines Agency Priority Medicines (PRIME) Designation for Accelerated Assessment of Complement 5a Receptor Inhibitor CCX168 for Treatment of Patients with ANCA-Associated Vasculitis 42

    May 23, 2016: ChemoCentryx Announces Presentation of Positive Results from Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 at the 53rd ERA-EDTA Congress 43

    Apr 28, 2016: ChemoCentryx Receives FDA Orphan Products Development Grant for Orally Administered Complement 5a Receptor Inhibitor CCX168 for Treatment of ANCA-Associated Vasculitis 45

    Jan 06, 2016: ChemoCentryx Announces Positive Results in Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 46

    Nov 05, 2015: ChemoCentryx Presents Phase II Results on CCX168 at the American Society of Nephrology Annual Meeting 47

    Aug 19, 2015: UNMC spinoff company to test H1N1 vaccine in animal trial 48

    Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis 49

    Nov 20, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in Atypical Hemolytic Uremic Syndrome Treatment by the FDA 49

    Nov 17, 2014: ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit In Non-Renal ANCA Vasculitis Disease Activity, In Addition To Previously Shown Kidney Disease Improvements 50

    Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA 51

    Jun 02, 2014: ChemoCentryx's Orally-Administered Complement 5a Receptor Inhibitor, CCX168, Shows Benefit in ANCA-Associated Vasculitis Based on Birmingham Vasculitis Activity Score and Renal Disease Measurements 51

    Dec 03, 2013: ChemoCentryx Announces Positive Top-Line CCX168 Phase II Data in ANCA-Associated Renal Vasculitis 52

    Dec 07, 2012: Penn-Led Research Suggests A New Strategy To Prevent Or Halt Periodontal Disease 54

    Appendix 56

    Methodology 56

    Coverage 56

    Secondary Research 56

    Primary Research 56

    Expert Panel Validation 56

    Contact Us 56

    Disclaimer 57

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

20634 | GMDHC0609TDB

Number of Pages

57

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! C5a Anaphylatoxin Chemotactic Receptor 1 - Pipeline Review, H2 2019
C5a Anaphylatoxin Chemotactic Receptor 1 - Pipeline Review, H2 2019SummaryC5a Anaphylatoxin Chemotac...
25 Nov 2019 by Global Markets Direct USD $2,975 (normally
USD $3,500)
More Info
SAVE 15% today! C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H1 2019
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H1 2019SummaryC5a Anaphy...
29 Apr 2019 by Global Markets Direct USD $2,975 (normally
USD $3,500)
More Info
SAVE 15% today! C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H2 2018
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H2 2018SummaryC5a Anaphy...
14 Aug 2018 by Global Markets Direct USD $2,975 (normally
USD $3,500)
More Info
SAVE 15% today! C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H1 2018
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H1 2018SummaryC5a Anaphy...
13 Feb 2018 by Global Markets Direct USD $2,975 (normally
USD $3,500)
More Info
SAVE 15% today! C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) – Pipeline Review, H2 2017
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H2 2017SummaryC5a Anaphy...
16 Aug 2017 by Global Markets Direct USD $2,975 (normally
USD $3,500)
More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H2 2016 [Published by Global Markets Direct] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...